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The potential of genetically modiﬁed cardiomyoblasts in treating damaged myocardium is well known. However, eﬃcient delivery
of these cells is of major concern during treatment. The limiting factors are the massive cell death that occurs soon after their
intramyocardial transplantation into the beating heart. To address these problems, we generated recombinant baculoviruses
(BacMam viruses) which eﬃciently transduced cardiomyoblast cells under optimized conditions. These genetically modiﬁed
cells were then protected in a new polymeric microcapsule using poly-ethylene-glycol (PEG), alginate, and poly-L-lysine (PLL)
polymers for eﬃcient delivery. Results showed that microcapsules maintain cell viability and support cell proliferation for at least
30 days. The capsules exhibit strong immunoprotective potential and have high mechanical and osmotic stability with more than
70% intact capsules. The encased transduced cells showed a rapid transgene expression inside the capsule for at least 15 days.
However, preclinical studies are needed to further explore its long-term functional beneﬁts.
1.Introduction
Thepathologicalﬁndingsinischemicheartdiseasesarechar-
acterized by extensive cardiomyocyte apoptosis, necrosis,
and replacement of myocardial tissue with noncontractile
ﬁbrous cells after myocardial infarction. Since mature car-
diomyocytes are terminally diﬀerentiated cells, their natural
replacement with ﬁbrous tissue results in permanent loss
of contractile myocardium and the formation of dilated
congestive heart failure (CHF) [1]. Thus, embryonic or
fetal origin cardiomyocytes become an important focus for
cell therapy and cell-based gene therapy for the treatment
of CHF [2]. However, the success of such experimental
therapies relies mainly on their biosafety proﬁles, eﬃciencies
of gene transfer for cell-based gene therapies, and suitable
cell transplantation and supporting constructs. A lot of
emphasis has been given to transplantation of neonatal
cardiomyocytes, skeletal myoblasts, embryonic stem cells,
marrow stromal cells, and genetically modiﬁed cells using
biocompatible scaﬀolds to repair the damaged myocardial
tissues [3–6]. The diﬀerent types of scaﬀolds include natural
matrices, such as collagen tubes, alginate hydrogels, and
ﬁbrin mesh [7–9]. 3-dimentional constructs using collagen
and matrigel are also being proposed for eﬃcient cell trans-
plantation [10, 11]. Another approach is to utilize thermo-
sensitivepolymersandelectrospunnanoﬁbre-basedscaﬀolds
topreparebiograftsthatcanpromotebettercellproliferation
aswell as implant biodegradability [6, 12, 13].Biodegradable
polymers,suchaspolyurethane,carbonate,polyglycolicacid,
polycaprolactone, and polylactic acid, are also being used
for this purpose. A few of them have produced signiﬁcant
resultsinpreclinicalandclinicalsettings[14].However,these
modes of cell delivery have common drawbacks. Apart from
highchancesofgettingimmunerejection,amajorportionof2 Journal of Biomedicine and Biotechnology
the transplanted cells get damaged soon after injection, and
most of the remaining biologically active cells get washed out
by the beating heart [15, 16].
Artiﬁcial cell microencapsulation, a concept in which
biologically active materials are encapsulated in specialized
ultrathin semipermeable polymer membranes, has been
proposed here as means to address the above-mentioned
problem [17–19]. These microcapsules provide a large
surface area to volume ratio which promotes rapid dif-
fusion of oxygen, nutrients, and waste metabolites. The
semipermeable membrane of such microcapsules excludes
antibodies, tryptic enzymes, and external materials but
allows smaller molecules like peptides to enter and diﬀuse
out of the cell [17, 20, 21]. Previous in vivo studies using
standard APA microcapsules were not suitable for long-term
transplantation, where it was often followed by encapsulated
cellnecrosisandﬁbrotictissuegrowtharoundthemembrane
surface [22–24].
In this study, recombinant baculoviruses carrying Mon-
ster Green Fluorescent Protein gene under the control of
mammalianCMVpromoterweregenerated(Bac-MGFP)for
genetically modifying the cardiomyocytes before encapsu-
lation. Detailed studies to optimize the transduction con-
ditions with minimum cytotoxicity towards the cardiomy-
ocytes, including the eﬀects of epigenetic factors [25], were
done. These modiﬁed baculoviruses, known as BacMam
viruses for carrying mammalian expression cassettes, are
considered to be biologically safe as they cannot replicate
or express their own genes in mammalian cells [26, 27].
The genetically modiﬁed cells were then encapsulated in
AP-PEG-A microcapsules and evaluated for their potential
in giving immunogenic and mechanical protections to the
entrapped embryonic cardiomyocytes against the harsh
external environment, which is particularly important for
cell transplantation to the beating heart.
2.MaterialsandMethods
2.1. Insect Cell Cultures. Sf9 insect cells (Invitrogen Life
Technologies, Carlsbad, CA) were maintained at 27◦Ci n
SF900 III serum-free medium in stationary ﬂasks. The
cells were maintained in exponential growth phase and
s u b c u l t u r e dt w i c ep e rw e e k .F o rl a r g e rv o l u m e s ,c e l l sw e r e
grown in shaker ﬂasks (Erlenmeyer, Corning) while being
agitated with 120rpm at 27◦C incubator shaker [28, 29].
2.2. Construction of BacMam Vector. The pVL1392 baculovi-
ral transfer vector and phMGFP vector carrying the Monster
Green Fluorescent Protein (MGFP) were obtained from
BD Biosciences and Promega, respectively. The phMGFP
and pVL1392 vectors were digested with BglII and XbaI
restriction enzymes. The cutout PCMV−hMGFP gene from
phMGFPandlinearizedpVL1392vectorwereligatedtoform
the pVL1392-PCMV-PMGFP transfer vector.
2.3. Cotransfection of Insect Cells and Generation of the Bac-
MGFP Viral Stock. To generate the recombinant MGFP
baculoviruses, 1 × 106 Sf9 cells were seeded in 6-well plates,
and transfection procedure was followed using previously
described method [30]. Brieﬂy, a transfection mixture, com-
prising of 1μg of the constructed BacMam transfer vector,
linearized baculovirus DNA (BD Baculogold), and 6μLo f
the Cellfectin transfection reagent diluted in 200μL SF900
III media (Invitrogen Life Technologies, Carlsbad, CA), was
prepared. The mixture was incubated for 45 minutes at
room temperature and then cotransfected to the seeded cells.
After 5hr of incubation at 27◦C, the transfection media
was replaced with Sf900III media, and the cells were further
incubated at 27◦C. 96h after transfection, the cell cultures
were collected, centrifuged at 1000xg for 10min, and
then the supernatant containing the baculovirus was ﬁltered
through a 0.22-μm membrane and stored at 4◦C( P 0V i r u s
Stock). The viral stock, measured in terms of plaque forming
unit (pfu), was ampliﬁed by scaleup in shaker ﬂask cultures
[28, 29]. Brieﬂy, Sf9 cells were grown till mid-exponential
phase and diluted to 2×106 cells/mL with SF900III medium.
The cultures were infected with P0 virus stock at an MOI
(pfu/cell) of 0.1. During the infection process, the total
and viable cell densities were measured using trypan blue
in hemocytometer. The infected cell culture containing
the ampliﬁed recombinant baculoviruses was harvested (P1
stock) by centrifugation when cell viability was between
75 and 80%. Baculovirus with the CMV promoter and no
MGFP gene (Bac-null) was also generated in a similar way.
2.4. Quantiﬁcation of Baculoviral Titre by Immunological
Assay. The viral titre, measured as plaque forming unit
(pfu)/ml was determined using Novagen’s Baculovirus Fast
Plax Titer Kit according to the manufacturer’s protocol. The
Sf9 cells were plated in 6-well plate with 1 × 106 cells per
well.AfterserialdilutionoftheviralstocksinSf900IIImedia,
the 200μL aliquots were added to each well. At the end of
1hr incubation, 2mL media was added to each well followed
by 30h incubation at 27◦C in a sealed humid chamber. The
cells were then washed twice with PBS (Invitrogen) and
ﬁxed in 3.7% formaldehyde solution. After blocking the cells
with 1% gelatin, Fast Plax monoclonal primary antibody
(diluted 1:10,000), speciﬁc to the baculovirus glycoprotein
64, was added to the cells. After 1h incubation, the cells
were washed in wash buﬀer (10mM Tris-HCl pH 8.0, 0.15M
NaCl, 0.1% Tween-20) and incubated for another 1h with β-
galactosidase- conjugated goat antimouse antibody (diluted
1:100). This was followed by X-Gal staining which detects
the single infected cells and foci of infected cells by their dark
blue color.
2.5. Culture and Transduction of Cardiomyocytes. The H9c2
myogenic cell line derived from embryonic rat heart ventri-
cles was obtained from American Tissue Culture Collection
(CRL 1446) and cultured in DMEM supplemented with
10% FBS. The cells were routinely maintained as stationary
cultures in T-75 ﬂasks, incubated at 37◦Ci nac o n t r o l l e d
environment with 5% CO2. To check the GFP ﬂuorescein
expression, 2 × 104 cells/well were seeded in 96-well plates
and transduced for 6h with baculoviruses at varied MOI
resuspended in 200μL PBS at 27◦C. The viral solution wasJournal of Biomedicine and Biotechnology 3
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Figure 1: Schematic representation of molecular cloning strategy for generation of recombinant BacMam virus and microencapsulation
of transduced cells. The reporter gene hMGFP was excised along with the CMV promoter from phMGFP vector using BglII and XbaI
restriction enzymes and inserted in the MCS of the baculovirus transfer vector pVL1392 to construct the PCMV−hMGFP/pVL1392 plasmid. The
BacMam viruses generated by cotransfection were transduced to the cardiomyocytes. This was followed by microencapsulation and tracking
the MGFP expression of the transduced cells.
replacedwith200μLcellmediumsupplementedwith10mM
NaBu or only cell medium. 24 hour posttransduction (hpt),
ﬂuorescein readings (485nm/535nm) of the individual wells
were taken with the plate reader (Victor3 Multilabel Counter
from Perkin Elmer).
2.6. PCR Analysis. The cardiomyocyte cells were seeded in
6-well plates at 5 × 105 cells/well using serum-supplemented
DMEM media and were allowed to attach overnight in the
incubator. For transduction, the cell medium was replaced
by 500μL of PBS containing either Bac-MGFP virus or no
virus. After 6h of viral incubation at 27◦C, the viral solution
was removed, and the cells were washed twice in PBS and
replenished with 2mL of fresh media treated with or without
10mM NaBu for further culture in the 37◦C incubator. For
detection of MGFP gene in the cells 24hpt, total DNA was
extracted from 1 × 106 transduced and mock-transduced
cells cultured in 6 well plates using the DNA extraction kit
(from Qiagen), according to the manufacturer’s instructions.
The obtained DNA was then PCR ampliﬁed using Taq DNA
Polymerase (Invitrogen), following the conditions given in
Table 1. Ampliﬁcations were carried out for 25 cycles at 94◦C
for 35sec (denaturation), 55◦C for 35sec (annealing) and
72◦C for 25sec (extension).
2.7. Cytotoxicity Assay Using Factorial Matrix Design Exper-
iments. The cytotoxicity for the virus and sodium butyrate
(NaBu) as the histone deacetylase inhibitor was evaluated
using the Cell Titer 96 Aqueous Nonradioactive Cell Prolif-
eration MTS Assay (Promega). MTS is chemically reduced
by viable cells into formazan, which is soluble in tissue
culture medium. The dehydrogenase enzyme activity found
in the metabolically active cells is measured in terms of light
absorbance values in this assay. The measurement of the
absorbance of the formazan was carried out using the plate
reader (Victor3 Multilabel Counter from Perkin Elmer) at
490nm. Since the production of formazan is directly related
to the number of living cells, the intensity of the produced
color is an indicator of the viable cells. The factorial design
experimentsweredonetocheckthevariationintoxicitylevel
of H9c2 cells with respect to MOI and NaBu concentration
using Design-Expert software as used earlier [28]. For this,
the cardiomyocyte cells were seeded in a 96 well plate with
2 × 104 cells per well using serum-supplemented DMEM.4 Journal of Biomedicine and Biotechnology
Table 1: Primer sequences used in PCR.
Gene Forward sequences Reverse sequences
Annealing
temp
(cycles)
Product
size
(bp)
MGFP 5
 GATGCAGCGCAAGACCCTAAAG3  5
 GGTCTTGAAGTCGCAGCGGTAG3
 
55◦C (25) 133
GAPDH 5
 TCAAGGGCATCCTGGGCTAC3
  5
 AAGTGGTCGTTGAGGGCAATG3
 
55◦C (25) 112
200x
Infected Sf9 cells
Figure 2: Immunological staining of baculovirus-infected Sf9 cells
using FastPlax Titre kit. The Sf9 cells were infected with diluted
baculoviral stock, and after 24hrs the cells were ﬁxed, and gp64
protein was detected on the cell surfaces by using monoclonal anti-
gp64 antibody and β-galactosidase-conjugated secondary antibody.
The Bac-null was added to the seeded cells with varied range
ofMOI(500to2000)inpresenceofDMEM+10%FBS.This
was followed by addition of NaBu (ranging from 0mM to
20mM) to the infection media after an incubation time of
6h. After 48h the cytotoxicity test was done by MTS assay
as per the manufacturer’s instructions mentioned in earlier
work [31]. The experiments were performed in triplicates.
2.8. Encapsulation of Cardiomyocytes in Polymeric Micro-
capsules. The H9c2 cells were encapsulated in alginate
microcapsules using our previously established procedures
[23, 32, 33]. Transduced or nontransduced H9c2 cells were
suspended in 1.5% sodium alginate (Sigma Chemicals, St.
Louis, MO, USA) at a cell concentration of 2 × 106 cells/mL.
The suspension was extruded through an encapsulator
(Inotech) ﬁtted with a 300μm nozzle at a voltage of
0.577kV and frequency of 710Hz. The gelation process
took place in a 0.1M CaCl2 solution for 15min. The newly
generated alginate microcapsules were immersed in 0.05%
(w/v) poly-l-lysine (PLL; Sigma Chemicals) solution for
10min. The PLL-coated alginate capsules were immersed in
0.5% solution of PEG dissolved in 0.45% NaCl for 15min.
The capsules were washed twice with physiological solution
before every coating and then subjected to a ﬁnal coating of
0.1% alginate. The washed capsules were then transferred to
stationary cell culture ﬂasks resuspended in DMEM medium
supplemented with 10% FBS and antibiotic antimycotic
solution (Sigma) for further culture in 37◦C incubator with
5% CO2. Microcapsules were replenished with fresh media
every alternate day.
2.9. Tracking the Cell Growth and Viability of Microencap-
sulated Cells. Growth of the cells within microcapsules was
assessed using polyanionic calcein AM dye (Biotium Inc.,
Hayward, USA). Using the dye, the live cells were detected
by the intracellular esterase-mediated conversion of the
nonﬂuorescent cell-permeant calcein AM to the ﬂuorescent
green calcein [34]. 50 microcapsules, encapsulating the cells,
were ﬁrst washed with PBS and incubated with 200μL
of fresh PBS containing 2μM calcein AM. After 1h, the
wells were checked under the ﬂuorescence microscope,
and ﬂuorescein measurements (excitation 485nm, emission
535nm) of the wells were taken with a plate reader (Perkin
Elmer). The background ﬂuorescence detected in the wells
with microcapsules having no cells was taken as the negative
control.
To assess the percentage of cells viable within the micro-
capsules, calcein AM and ethidium homopolymer EthD-III
dyes (Biotium Inc., Hayward, USA) were used. The dyes
help to diﬀerentiate the viable and dead cells within the
microcapsules. The dead cells were detected by the bright
red ﬂuorescence emitted by EthD-III dye on binding with
the nucleic acids, which enters only dead cells through their
damaged membranes. The microcapsules were ﬁrst washed
twice with PBS, 10min each, and resuspended in fresh
PBS buﬀer. 2μM calcein AM and 4μM EthD-III were then
added to the microcapsules and incubated for 1h before
checking under the ﬂuorescence microscope. The numbers
of microencapsulated ﬂuorescent green cells were counted
a g a i n s tﬂ u o r e s c e n tr e dc e l l si nt h r e ed i ﬀerent experiments,
and the average percentageviability of intracapsular cells was
calculated.
2.10. Stability Test of the Microcapsules. The mechani-
cal stability of the AP-PEG-A microcapsules was deter-
mined by applying a joint osmotic pressure and rotational
stress test [35]. The osmotic pressure test was performed
by directly transferring 500 microcapsules, encapsulating
known amount of cells, previously stored in 0.85% saline
solutionto5mLdeionizedwaterina25mLvolumetricﬂask.
To implement the rotational stress, the capsules suspended
in hypotonic solution (deionized water) were then shaken
in a horizontal shaker (Environ) at a speed of 150rpm
at 37◦C for 120min. In order to assess the ability of the
microcapsulestowithstandthesestresses,photomicrographs
of the microcapsules were taken at diﬀerent time points.
Samples were also collected from time to time for countingJournal of Biomedicine and Biotechnology 5
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Figure 3: Eﬀect of NaBu and viral dose in H9c2 cells’ transgene expression. Cells were transduced with Bac-MGFP for 6h in PBS at 27◦C
withandwithout10mMNaButreatmentatdiﬀerentviraldoses.Quantiﬁcation(ﬂuoresceinexpression)ofﬂuorescentinH9c2cells(a)were
made with relation to viral dosage 24hpt. The average ﬂuorescein-expressed (excitation 485nm, emission 535nm) values were normalized
to that of the cells having 6h of viral incubation in presence of PBS (taken as 100%) and are represented as normalized mean expression in
percentage value. The data represent mean of three diﬀerent readings. (b) Fluorescence images of transduced cells in absence and presence
of NaBu are shown 24hpt. (c) Detection of MGFP plasmid delivery in H9c2 cells 24hpt in presence or absence of NaBu by standard
PCR analysis. Cells were given equal viral dose with same viral incubation time. Nontransduced cells were taken as the control (mock) for
the transduction procedure. The DNA was extracted from the transduced cells 24h after transduction, and PCR analysis was done using
primers that amplify the delivered MGFP gene. Ampliﬁcation of housekeeping GAPDH gene serves as an internal control for the eﬃciency
of polymerase reaction. Molecular weight (Mw) markers are low range DNA ladder. The similar band intensities in the agarose gel indicates
that there was equal viral transduction in both +NaBu and −NaBu groups, although the corresponding protein expression was higher in
+NaBu (as shown in (a) and (b)). This proves that NaBu does not interfere in viral transduction procedure but signiﬁcantly improves the
transgene expression.
the number of free cells, using hemocytometer, which were
released from the ruptured capsules. Thus, the percentage of
cellsthatremainedentrappedinsidetheintactmicrocapsules
with time was calculated.
2.11. Immunoprotective Behavior of the Microcapsules against
Lymphocytes. In order to investigate the potential of the
membrane to provide immunoprotection to the encapsu-
lated cells, 50 AP-PEG-A capsules encapsulating the cells
were cocultured in 1mL of media containing 5 × 104
lymphocytes per well of a 24-well plate [23]. As the lym-
phocytes secrete cytokines, the viability of the encapsulated
cardiomyocyte cells will depend on the immunoisolation
properties of the capsular membrane. Capsules were with-
drawn periodically to test the viability of the encapsulated
cardiomyocytes by calcein AM and EthD-III dyes using the
procedure mentioned above.
2.12. Microencapsulation of Baculovirus-Transduced Cells.
H9c2 cells were transduced with Bac-MGFP at an MOI
o f3 0 0f o r6 ha t2 7 ◦C. They were then encapsulated at a
concentrationof2×106 cellspermLofalginatethatfollowed
further coatings to prepare the AP-PEG-A microcapsules.
The encapsulated cells were then cultured in stationary6 Journal of Biomedicine and Biotechnology
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Figure 5: Cell survival and growth kinetics of the Bac-null
transduced cells encapsulated in AP-PEG-A microcapsules. For the
encapsulation 2×106 cells/ml of alginate were used and maintained
in DMEM + 10% FBS at 37◦C and were incubated for 30 days.
Medium was replaced at alternate days. Experimental samples were
treated with calcein AM for 1h, and they were measured using
ﬂuorescence plate reading at excitation 485nm, emission 535nm.
ﬂasks in 10% DMEM medium supplemented with FBS and
antibiotics. At diﬀerent time intervals, 50 microcapsules
containing the transduced cells were collected, washed with
PBS, and resuspended in 200μL of fresh PBS in 96-well
plates. The wells were checked under ﬂuorescence micro-
scope, and ﬂuorescein measurements (excitation 485nm,
emission 535nm) of the wells were taken with a plate reader
(Perkin Elmer). The background ﬂuorescence as detected in
the wells with microcapsules with no cells was taken as the
negative control.
3. Results andDiscussion
3.1. Generation of Recombinant Bac-MGFP Viruses from
Insect Cell Culture. The recombinant baculovirus was con-
structedasdepictedinFigure1usingtheBacMamexpression
system. This is a powerful tool for diﬀerent gene therapy
applications as it combines the advantages of highly eﬃcient
transient transgene expression, ease in generation, and a
wide cell tropism [27]. Although the transient expression
can be termed as a kind of backlog to the system, it is a
muchdesirablefeature,thinking frombiosafetyperspectives.
The transient expression is attributed to the lack of natural
mechanism of baculovirus to integrate with the host genome
which, on the other hand, is an inherent nature of the
commonly used mammalian viruses such as adenovirus,
adeno-associated, and lentivirus [28, 30]. Where these
mammalian viral vectors have the probability to randomly
integrate into the host’s crucial genomic regions, thereby
resulting in unexpected tumorigenesis, baculovirus holds a
much better safety proﬁle. Many safety issues are currently
under consideration with present mammalian virus-based
gene therapy trial [29]. At this point in time, insect cell
speciﬁc baculovirus can play an important role as a potential
biologically safe gene delivery vehicle.
The titre of the virus stock obtained in our studies
was 2.4 × 109 pfu/mL as determined by the immunological
assay method originally developed by Kitts and Green [36].
The advantage of this method is that it quantiﬁes the
infectious particles within 20–48h using Sf9 cells, whereas
other methods, like the end-point dilution method and
plaque assay method, take 7 to 10 days to quantify [26].
Quantiﬁcation techniques for baculovirus titration also
includes usage of viable cell size [37], q-PCR [38], and
ﬂuorescence labeling [39]. The current method uses the
immunological techniques to detect the baculoviral external
glycoprotein gp64 on the infected Sf9 cell surface. The dark
blue color plaques in Figure 2 show the insect cells infected
with baculovirus 24h after infection, where the baculoviral
gp64 was detected by using monoclonal antibody against it.
3.2. Modulation of Transgene Expression by Regulating the
Transduction Parameters: Viral Dosage and Treatment with
Epigenetic Factor. In order to optimize the in vitro transduc-
tion eﬃciency of baculovirus in rat cardiomyocytes various
critical parameters were considered. To investigate, 2 ×
104 H9c2 cardiomyocytes, were seeded in 96-well plates
and transduced with 200μL PBS containing Bac-MGFP of
various doses under transduction temperature of 27◦C. After
6hoftransduction,thecellswerewashedtwicewithPBSand
replenished with fresh medium containing 10mM sodium
butyrate or only medium. The viral dose plays an important
role in transduction of H9c2 cells which is evident for the
data in Figure 3(a), where a gradual increase of viral dose
from MOI of 50 to 300 shows a corresponding increase in
transgeneexpressionwhileahigherMOIof600didnotshow
furtherincreaseofexpression.Thus,MOIof300wasoptimal
for H9c2 cells.
To examine whether epigenetic modiﬁcations can regu-
late gene expression 10mM sodium butyrate was added to
the replaced DMEM media after transduction and incubated
in the incubator for 24h. Figure 3(a) shows that the histone
deacetylase inhibitor has a positive eﬀect on gene expression
of the cells transduced with equal MOI. It demonstrates thatJournal of Biomedicine and Biotechnology 7
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theH9c2cardiomyocytes’GFPexpressionwasalmostdouble
in NaBu-treated cells with respect to nontreated cells, and
this result was consistent under diﬀerent viral doses. The
ﬂuorescence image of Figure 3(b) represents an example of
the positive eﬀe c t so fv i r a ld o s a g ea n dN a B uo nH 9 c 2c e l l
expression.
PCR analysis was done on the transduced cells to show
that, although there was a marked diﬀerence in the amount
of transgene protein expression level between the NaBu-
treated and nontreated cells, they had same amount of
MGFP transgene DNA present within them due to equal
viral dosage. Thus, Figure 3(c) reconﬁrmed that it was only
the treatment of NaBu that upregulated the transcription
of MGFP within the cells by inducing the acetylation of
histones. This, in other words, illustrates that higher levels
of expression are achievable in recombinant baculovirus-
transduced cells by the application of NaBu, which results
in an increase in the expression by blocking deacetylation of
histone proteins bound to DNA.
But unlike the other viruses, baculovirus generally
shows a lower transduction level in vivo because of serum
inactivation due to complement sensitivity [40]. Blocking
the C component 5 of the complement system using
antibody or cobra venom factor enhances the transduction
level signiﬁcantly. Recent animal studies have also revealed
that simple coating of viral particles with polycationic
polyethylenimine polymers can produce serum-resistant
baculoviruses [41, 42]. Here, through ex vivo transduction
of the cardiomyocytes, we are averting the possibility of
ineﬃcient gene delivery through in vivo viral inactivation.
Moreover, transplanting genetically modiﬁed cells makes the
delivery system biologically much safer in comparison to
direct viral delivery in vivo. A wide range of mammalian
viruses, such as lentivirus, adenovirus, and adeno-associated
virus, have shown to eﬃciently transfer transgene in vivo to
cardiac cells for myocardial therapy [43–45]. An illustrative
work by Grassi et al. showed that both adenovirus and
baculovirus transduce human cardiomyocytes equally and
eﬃciently [25]. Using cellular DNA replication analysis, the
group also showed that adenoviral vector has a major and
more extended harmful eﬀect on cardiovascular cells than
insect cell-originated recombinant baculoviruses. Another
work by Pieroni et al. showed that baculovirus express-
ing vesicular stomatitis virus glycoprotein in its envelope
can transduce the mouse myoblasts and myotubes more
eﬃciently than normal baculovirus which lacks the gly-
coprotein [46]. The group also performed in vivo studies
which showed that the modiﬁed baculovirus can eﬃciently
transfer gene in mouse skeletal muscle, and the persis-
tence of this transgene expression depends on the mouse
strain.
3.3. Detection of Cytotoxic Eﬀects of Baculovirus and NaBu
on Cardiomyoblasts. In order to evaluate the individual and
combinatorial toxic eﬀects of baculovirus and NaBu on8 Journal of Biomedicine and Biotechnology
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Figure 7: Immunoprotective potential of the AP-PEG-A membrane. Microcapsules were prepared by microencapsulating 2 × 106 Bac-null
transduced H9c2 cells/ml of alginate and cultured in DMEM+10% FBS in 37◦C incubator for 8 days in presence of lymphocytes. Medium
was replaced on every alternate day. Samples were collected at regular intervals and subjected to viability test. Viability tests were done by
using the calcein AM (showing viable cells in green) and ethidium homopolymer (showing dead cells in red) dye. The data represent the
mean of three independent studies, and error bars represent standard error of the mean (a). Representative bright ﬁeld and ﬂuorescent
images of a capsule encapsulating the cells under 200x magniﬁcations in a ﬂuorescence microscope (b). The white-dotted circles show the
peripheral surface of the capsules.
Table 2: Factors checked in toxicity test for H9c2 and their
concentrationsinfactorialdesignexperiment.Thecellsweretreated
withthecomponentsfor48hrsbeforeperformingthetoxicityassay.
Factors Name Fixed levels used
Low Mean High
A MOI (pfu/cell) 500 1250 2000
B NaBu (mM) 0 10 20
thecells,factorialmatrixdesignexperimentswereperformed
and optimized for ideal viral dose and NaBu concentration
with respect to cell toxicity percentage as measured by MTS
assay. The cytotoxic factors and the range of study are
mentioned in Table 2. The graph generated by the Design-
Expert software in Figure 5 demonstrates that there is no
signiﬁcant cytotoxic eﬀect (viability ∼99%) of high Bac-
null viral dose (MOI: 2000) on the cells even when exposed
for 48h, in absence of NaBu. While NaBu enhances gene
expression, it also has a toxic eﬀe c to nt h ec e l l sa si se v i d e n t
by the low viability percentage of the cells when exposed to a
highconcentrationofNaBu for48h.Thus,performingmore
experimentsbasedonthefactorialmatrixdesignexperiment,
we optimized that a low concentration of 10mM NaBu
with a lesser exposure time of 24h is optimum to achieve
maximum expression level with minimum cytotoxic eﬀects.
3.4. Examining the Biocompatibiity of the PEG-Integrated
Microcapsules by Monitoring Cell Growth. To test if the PEG-
incorporated capsules supports cell survival and prolifera-
tion, Bac-null transduced H9c2 cells were encapsulated in
AP-PEG-A microcapsules with the same cell density. The
starting average cell population per capsule was around
90 cells. Using calcein staining, the total number of viable
cells per capsule was measured and calculated through
the ﬂuorescence plate reader at diﬀerent time intervals.
For this, a standard curve of ﬂuorescein absorbance with
predetermined number of calcein-stained encapsulated cells
was used as the reference. The anchorage-dependant cells
were able to survive inside both types of alginate capsules.
The graph in Figure 6 shows an increase in cell number from
day 6 to day 12. This shows that the cells can proliferate
inside the PEG-incorporated microcapsules. The graph also
showed that after day 12 there was a drop of viable cell
count in the capsules, but it maintained an average viable
cell count above 100 per capsule for at least 30 days. Thus, it
is evident that capsules have a good biocompatibility proﬁle
with H9c2 cells and that there is no adverse eﬀect on the
cell survival and growth kinetics due to incorporating PEG
layer to the capsules. The capsular shape also solves the
limitations associated with other delivery systems, such as a
thick scaﬀold system, where with increasing cellular density
there arises a major diﬃculty in transfer of oxygen andJournal of Biomedicine and Biotechnology 9
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Figure 8: Time-course proﬁle of transgene expression of AP-PEG-A microencapsulated H9c2 cells transduced with Bac-MGFP under
optimal transduction condition. The average ﬂuorescein-expressed values (excitation 485nm, emission 535nm) were normalized to that
of cells with 24hpt having 6h of viral incubation in presence of PBS (taken as 100%) and are represented as normalized mean expression in
percentagevalue(a).Thedatarepresentthemeanofthreediﬀerentﬁelds,anderrorbarsrepresentstandarderrorofthemean.Representative
photographs of corresponding transduced microencapsulated cells were taken using ﬂuorescence microscope under 100x magniﬁcation at
diﬀerent days after encapsulation (b). The white-dotted circles show the peripheral surface of the capsules.
nutrients to all the cells [11]. This leads to the need of a
perfusion system through a core vessel to provide oxygen
within the scaﬀold [47]. In comparison, the larger exposed
surface area of the capsules allows easy diﬀusion of nutrients
and metabolites in and out of the capsule encapsulating a
high density of cells.
3.5.MechanicalandOsmoticStabilityoftheAP-PEG-AMicro-
capsules. To evaluate the mechanical and osmotic stability of
the PEG-modiﬁed membrane, the cell-encapsulatedcapsules
were subjected to rotational and osmotic stress as mentioned
in Section 2. The AP-PEG-A microcapsules were able to
withstand the combined mechanical and osmotic forces
as evident in the graph of Figure 7(a), representing the
percentage of cells still encapsulated. 75% of the cells
remained encapsulated in AP-PEG-A microcapsules after
1h, which reduced marginally to only 71% after 2h. The
observed stability can be because of the penetration of PEG
into the alginate core of the capsule that gives an added
stability to the capsule when exposed to stress conditions
[48]. The reason for such high stability can also be attributed
to the strong interpenetrating network formed by PEG on
the capsular surface.
3.6. Immunoprotective Potential of the AP-PEG-A Micro-
capsules. The ability of the AP-PEG-A capsules to provide
immunogenic protection to the encapsulated cells were stud-
ied by coculturing microencapsulated Bac-null transduced
H9c2 cells with lymphocytes derived from mouse origin
for 8 days. It can be concluded from Figure 8(a) that the
average viability of the AP-PEG-A encapsulated cells started
to decrease signiﬁcantly only from day 8 (87%). That means
thatthe capsuleswereableto withstand the externalimmune
forces for at least 8 days, which is much longer and stronger
than other commonly used delivery systems [22]. This is
because it is important to have microcapsules with mini-
mum surface charges to avoid foreign body reactions when
transplanted [49]. The positively charged PLL binds with
negatively charged alginate through electrostatic interaction
which results in interfacial adsorption of PLL forming a thin
layer of PLL on the alginate core. An improper coating can
make the capsular surface charged. Hydrophilic, nonionic,
and the inert nature of PEG make it an ideal candidate
to neutralize the surface charge and hence increase the
immunoprotectivepotentialofthecapsulesbyalleviatingthe
chance of having surface protein adhesions [19, 50].
3.7. Transgene Expression Proﬁle of Baculovirus-Transduced
Cells Encapsulated in AP-PEG-A Microcapsules. In order
to demonstrate the gene expression pattern of the AP-
PEG-A microencapsulated transduced cells, H9c2 cells were
Bac-MGFP transduced and right away encapsulated at a
concentration of 2 million cells per ml of alginate to prepare
the AP-PEG-A microcapsules. The encapsulated cardiomy-
oblasts were then cultured in stationary ﬂasks in 10%
DMEM medium supplemented with FBS and antibiotics.10 Journal of Biomedicine and Biotechnology
The relative ﬂuorescence units of each well-containing 50
capsules resuspended in 200μL PBS were then measured on
diﬀerent time intervals using the Victor3 Multilabel Plate
Counter (Perkin Elmer, USA). Figure 8 reveals that the
transgene expression had a rapid expression pattern with
the highest expression observed on day 1, as is evident by
the normalized gene expression data with time. It shows the
highest expression (considered as 100%) on day 1, which
gradually diminished with days. The graph delineates that
the GFP expression level remained high at ∼50% on day 7
but dropped to ∼15% on day 9. This decrease in transgene
expression is mainly because of the transient nature of
cell expression mediated by baculovirus. This mechanism
could be beneﬁcial for cell-based gene therapy, where the
cells will express the transgene temporarily and stop after
the treatment period when its secretion will no longer be
needed. The cells can be genetically modiﬁed with diﬀerent
therapeutic genes based on the mode of treatment. So far,
bioengineered cardiomyocyte sheet grafts have been used
to induce myocardial angiogenesis [12, 51]. In fact, the
microcapsules can also be supplemented with the cocktail
of growth factors to promote neovascularization and better
survival rate of transplanted cells in vivo [52, 53].
4. Conclusion
Our results demonstrate that baculovirus can be eﬃciently
used to genetically modify murine cardiomyocytes under
our optimized transduction protocol. This is particularly
important as a gene delivery system because baculoviral
proteins cannot interact with host cell proteins and nucleic
acids, which can otherwise aﬀect the host cell cycle and its
viability. This makes this insect cell-originated viral vector
a biologically safe and eﬃcient vector for gene therapy
applications in comparison to mammalian viral vectors. Our
paper shows for the ﬁrst time that the genetically modiﬁed
cardiomyocyte cells can survive and even proliferate inside
the microcapsules.
Cardiaccelltransplantationislimitedmainlyduetopoor
graftviability[2].Ourrecentﬁndingsonanimalstudieshave
demonstrated that microencapsulated cell delivery system
can increase the transplanted cell retention capacity by four
times in comparison to free cells when injected intramyocar-
dially in a beating heart [16, 54, 55]. To further reduce the
biological and mechanical loss of the transplanted cardiomy-
ocytes in the harsh contractile myocardial environment,
we modiﬁed the alginate microcapsules by incorporating
PEG. This not only preserved the encapsulated cell viability
and proliferation potential but also increased mechanical
strengthandimmunoprotectivepotential.Baculovirustrans-
duced AP-PEG-A microencapsulated cells showed a rapid
expression of its transgene which persisted for at least two
weeks. In summary, this study suggests that recombinant
baculovirus-mediated genetically modiﬁed cardiomyocytes,
expressing therapeutic proteins, encapsulated in AP-PEG-
A microcapsules hold immense potential in myocardial
transplantationusingdirectintramyocardialrouteofadmin-
istration. This system can be implemented in the future
to transfer angiogenic transgene like VEGF through the
microencapsulated genetically modiﬁed cardiomyocytes to
reduce myocardial infarction and improve heart function,
although further research is needed to be done in vivo to
evaluate its potential for preclinical and clinical applications.
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